Reply to S.M. Sorscher and M.J. Hall et al

Affiliations

¹ Nadine M. Tung, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; and Judy E. Garber, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

Comment

Nadine M Tung et al. J Clin Oncol. 2016 Dec.

. 2016 Dec;34(34):4187-4188.

doi: 10.1200/JCO.2016.69.1022. Epub 2016 Oct 31.

¹ Nadine M. Tung, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; and Judy E. Garber, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

No abstract available

Comment on

Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, Hartman AR, Winer EP, Garber JE. Tung N, et al. J Clin Oncol. 2016 May 1;34(13):1460-8. doi: 10.1200/JCO.2015.65.0747. Epub 2016 Mar 14. J Clin Oncol. 2016. PMID: 26976419 Free PMC article.
Next-Generation Sequencing of Tumors to Better Estimate the Clinical Significance of Non- BRCA Germline Deleterious Mutations.
Sorscher SM. Sorscher SM. J Clin Oncol. 2016 Dec;34(34):4183. doi: 10.1200/JCO.2016.67.7724. Epub 2016 Oct 31. J Clin Oncol. 2016. PMID: 27551129 No abstract available.
Multigene Panels to Evaluate Hereditary Cancer Risk: Reckless or Relevant?
Hall MJ, Obeid E, Daly MB. Hall MJ, et al. J Clin Oncol. 2016 Dec;34(34):4186-4187. doi: 10.1200/JCO.2016.68.6725. Epub 2016 Oct 31. J Clin Oncol. 2016. PMID: 27551136 No abstract available.